Ben-Quan Qi
YOU?
Author Swipe
View article: Supplementary Figure S2 from Venetoclax plus Modified-Intensity Idarubicin and Cytarabine Treatment as First-Line Treatment for Newly Diagnosed Pediatric Acute Myeloid Leukemia
Supplementary Figure S2 from Venetoclax plus Modified-Intensity Idarubicin and Cytarabine Treatment as First-Line Treatment for Newly Diagnosed Pediatric Acute Myeloid Leukemia Open
Figure S2. Overall Survival and Event-free Survival Outcome (A) Overall survival (OS) according to risk group. (B) Event-free survival (EFS) according to risk group. (C) OS stratified by following HSCT status. (D) EFS stratified by followi…
View article: Supplementary Table S2 from Venetoclax plus Modified-Intensity Idarubicin and Cytarabine Treatment as First-Line Treatment for Newly Diagnosed Pediatric Acute Myeloid Leukemia
Supplementary Table S2 from Venetoclax plus Modified-Intensity Idarubicin and Cytarabine Treatment as First-Line Treatment for Newly Diagnosed Pediatric Acute Myeloid Leukemia Open
Table S2. Response outcomes of induction therapy
View article: Supplementary Table S1 from Venetoclax plus Modified-Intensity Idarubicin and Cytarabine Treatment as First-Line Treatment for Newly Diagnosed Pediatric Acute Myeloid Leukemia
Supplementary Table S1 from Venetoclax plus Modified-Intensity Idarubicin and Cytarabine Treatment as First-Line Treatment for Newly Diagnosed Pediatric Acute Myeloid Leukemia Open
Table S1. Study Representativeness Table
View article: Data from Venetoclax plus Modified-Intensity Idarubicin and Cytarabine Treatment as First-Line Treatment for Newly Diagnosed Pediatric Acute Myeloid Leukemia
Data from Venetoclax plus Modified-Intensity Idarubicin and Cytarabine Treatment as First-Line Treatment for Newly Diagnosed Pediatric Acute Myeloid Leukemia Open
Purpose:Venetoclax (VEN) has shown excellent activity in eliminating acute myeloid leukemia (AML) blasts in preclinical and clinical trials, but clinical data in pediatric newly diagnosed AML (ND-AML) remain limited. We evaluated VEN plus …
View article: Supplementary Figure S1 from Venetoclax plus Modified-Intensity Idarubicin and Cytarabine Treatment as First-Line Treatment for Newly Diagnosed Pediatric Acute Myeloid Leukemia
Supplementary Figure S1 from Venetoclax plus Modified-Intensity Idarubicin and Cytarabine Treatment as First-Line Treatment for Newly Diagnosed Pediatric Acute Myeloid Leukemia Open
Figure S1. Swimming plot of all study participants Each bar represents an individual patient. Patients with ongoing response still being treated on protocol at the time of last follow-up are indicated with arrow.
View article: Venetoclax plus Modified-Intensity Idarubicin and Cytarabine Treatment as First-Line Treatment for Newly Diagnosed Pediatric Acute Myeloid Leukemia
Venetoclax plus Modified-Intensity Idarubicin and Cytarabine Treatment as First-Line Treatment for Newly Diagnosed Pediatric Acute Myeloid Leukemia Open
Purpose: Venetoclax (VEN) has shown excellent activity in eliminating acute myeloid leukemia (AML) blasts in preclinical and clinical trials, but clinical data in pediatric newly diagnosed AML (ND-AML) remain limited. We evaluated VEN plus…
View article: [Mitoxantrone hydrochloride liposome combined with cytarabine for treating pediatric acute myeloid leukemia with RUNX1∷MTG16 fusion gene: a case report and literature review].
[Mitoxantrone hydrochloride liposome combined with cytarabine for treating pediatric acute myeloid leukemia with RUNX1∷MTG16 fusion gene: a case report and literature review]. Open
This case report presents a patient with pediatric acute myeloid leukemia (AML) with RUNX1∷MTG16, admitted to the Blood Disease Hospital of the Chinese Academy of Medical Sciences in October 2023. He was 13 years old, with a chief complain…
View article: [Next-generation sequencing-based minimal residual disease detection reveals clonal evolution in pediatric acute B-lymphoblastic leukemia: a case report and literature review].
[Next-generation sequencing-based minimal residual disease detection reveals clonal evolution in pediatric acute B-lymphoblastic leukemia: a case report and literature review]. Open
Minimal residual disease (MRD), a crucial biomarker for assessing efficacy and predicting recurrence, refers to residual tumor cells remaining in the body of patients with hematological malignancies who achieved complete remission after tr…
View article: Advancing Phage Therapy: A Comprehensive Review of the Safety, Efficacy, and Future Prospects for the Targeted Treatment of Bacterial Infections
Advancing Phage Therapy: A Comprehensive Review of the Safety, Efficacy, and Future Prospects for the Targeted Treatment of Bacterial Infections Open
Background: Phage therapy, a treatment utilizing bacteriophages to combat bacterial infections, is gaining attention as a promising alternative to antibiotics, particularly for managing antibiotic-resistant bacteria. This study aims to pro…
View article: Supplementary Figure S1 from Early Detection of Molecular Residual Disease and Risk Stratification for Children with Acute Myeloid Leukemia via Circulating Tumor DNA
Supplementary Figure S1 from Early Detection of Molecular Residual Disease and Risk Stratification for Children with Acute Myeloid Leukemia via Circulating Tumor DNA Open
Figure S1. Flowchart of patient selection and enrollment. In total, 50 patients and 195 paired samples (ctDNA and BM DNA) from this population can be analyzed. In the last row, plasma samples from included patients at separate timepoint we…
View article: Data from Early Detection of Molecular Residual Disease and Risk Stratification for Children with Acute Myeloid Leukemia via Circulating Tumor DNA
Data from Early Detection of Molecular Residual Disease and Risk Stratification for Children with Acute Myeloid Leukemia via Circulating Tumor DNA Open
Purpose:Patient-tailored minimal residual disease (MRD) monitoring based on circulating tumor DNA (ctDNA) sequencing of leukemia-specific mutations enables early detection of relapse for pre-emptive treatment, but its utilization in pediat…
View article: Supplementary Table S1 from Early Detection of Molecular Residual Disease and Risk Stratification for Children with Acute Myeloid Leukemia via Circulating Tumor DNA
Supplementary Table S1 from Early Detection of Molecular Residual Disease and Risk Stratification for Children with Acute Myeloid Leukemia via Circulating Tumor DNA Open
Table S1. Summary of targeted driver mutations for ctDNA detection
View article: Supplementary Figure S3 from Early Detection of Molecular Residual Disease and Risk Stratification for Children with Acute Myeloid Leukemia via Circulating Tumor DNA
Supplementary Figure S3 from Early Detection of Molecular Residual Disease and Risk Stratification for Children with Acute Myeloid Leukemia via Circulating Tumor DNA Open
Figure S3. Kaplan-Meier plot showed the PFS of patients diagnosed as CBF and non-CBF AML underwent dynamic monitoring of mutations by ctDNA from admission to the last cycle of chemotherapy. PFS, progression-free survival. CBF, core binding…
View article: Supplementary Figure S1 from Early Detection of Molecular Residual Disease and Risk Stratification for Children with Acute Myeloid Leukemia via Circulating Tumor DNA
Supplementary Figure S1 from Early Detection of Molecular Residual Disease and Risk Stratification for Children with Acute Myeloid Leukemia via Circulating Tumor DNA Open
Figure S1. Flowchart of patient selection and enrollment. In total, 50 patients and 195 paired samples (ctDNA and BM DNA) from this population can be analyzed. In the last row, plasma samples from included patients at separate timepoint we…
View article: Supplementary Figure S5 from Early Detection of Molecular Residual Disease and Risk Stratification for Children with Acute Myeloid Leukemia via Circulating Tumor DNA
Supplementary Figure S5 from Early Detection of Molecular Residual Disease and Risk Stratification for Children with Acute Myeloid Leukemia via Circulating Tumor DNA Open
Figure S5. Comparison of PFS stratified by the different timepoint post-treatment residual status either of plasma ctDNA or MFC at (A) C2D1, (B) C3D1 and (C) C4D1 post-treatment. ctDNA neg-MFC neg was defined as the VAF of mutation being n…
View article: Supplementary Figure S4 from Early Detection of Molecular Residual Disease and Risk Stratification for Children with Acute Myeloid Leukemia via Circulating Tumor DNA
Supplementary Figure S4 from Early Detection of Molecular Residual Disease and Risk Stratification for Children with Acute Myeloid Leukemia via Circulating Tumor DNA Open
Figure S4. The correlation of the VAFs in the patient-specific tumor mutation site detected in plasma ctDNA and matched MFC based MRD. Scatter plot of the 195 individual mutations detected by both methods (r=0.586, p<0.001).
View article: Supplementary Table S1 from Early Detection of Molecular Residual Disease and Risk Stratification for Children with Acute Myeloid Leukemia via Circulating Tumor DNA
Supplementary Table S1 from Early Detection of Molecular Residual Disease and Risk Stratification for Children with Acute Myeloid Leukemia via Circulating Tumor DNA Open
Table S1. Summary of targeted driver mutations for ctDNA detection
View article: Supplementary Table S2 from Early Detection of Molecular Residual Disease and Risk Stratification for Children with Acute Myeloid Leukemia via Circulating Tumor DNA
Supplementary Table S2 from Early Detection of Molecular Residual Disease and Risk Stratification for Children with Acute Myeloid Leukemia via Circulating Tumor DNA Open
Table S2. Representativeness of Study Participants
View article: Supplementary Figure S5 from Early Detection of Molecular Residual Disease and Risk Stratification for Children with Acute Myeloid Leukemia via Circulating Tumor DNA
Supplementary Figure S5 from Early Detection of Molecular Residual Disease and Risk Stratification for Children with Acute Myeloid Leukemia via Circulating Tumor DNA Open
Figure S5. Comparison of PFS stratified by the different timepoint post-treatment residual status either of plasma ctDNA or MFC at (A) C2D1, (B) C3D1 and (C) C4D1 post-treatment. ctDNA neg-MFC neg was defined as the VAF of mutation being n…
View article: Supplementary Table S2 from Early Detection of Molecular Residual Disease and Risk Stratification for Children with Acute Myeloid Leukemia via Circulating Tumor DNA
Supplementary Table S2 from Early Detection of Molecular Residual Disease and Risk Stratification for Children with Acute Myeloid Leukemia via Circulating Tumor DNA Open
Table S2. Representativeness of Study Participants
View article: Supplementary Figure S2 from Early Detection of Molecular Residual Disease and Risk Stratification for Children with Acute Myeloid Leukemia via Circulating Tumor DNA
Supplementary Figure S2 from Early Detection of Molecular Residual Disease and Risk Stratification for Children with Acute Myeloid Leukemia via Circulating Tumor DNA Open
Figure S2. Comparison of CIR stratified by the different timepoint post treatment residual status either of plasma ctDNA (A-C) or mutation in BM (D-F). CIR according to residual status either of plasma ctDNA (A) or mutation in BM (D) at C2…
View article: Supplementary Figure S2 from Early Detection of Molecular Residual Disease and Risk Stratification for Children with Acute Myeloid Leukemia via Circulating Tumor DNA
Supplementary Figure S2 from Early Detection of Molecular Residual Disease and Risk Stratification for Children with Acute Myeloid Leukemia via Circulating Tumor DNA Open
Figure S2. Comparison of CIR stratified by the different timepoint post treatment residual status either of plasma ctDNA (A-C) or mutation in BM (D-F). CIR according to residual status either of plasma ctDNA (A) or mutation in BM (D) at C2…
View article: Supplementary Figure S3 from Early Detection of Molecular Residual Disease and Risk Stratification for Children with Acute Myeloid Leukemia via Circulating Tumor DNA
Supplementary Figure S3 from Early Detection of Molecular Residual Disease and Risk Stratification for Children with Acute Myeloid Leukemia via Circulating Tumor DNA Open
Figure S3. Kaplan-Meier plot showed the PFS of patients diagnosed as CBF and non-CBF AML underwent dynamic monitoring of mutations by ctDNA from admission to the last cycle of chemotherapy. PFS, progression-free survival. CBF, core binding…
View article: Supplementary Figure S4 from Early Detection of Molecular Residual Disease and Risk Stratification for Children with Acute Myeloid Leukemia via Circulating Tumor DNA
Supplementary Figure S4 from Early Detection of Molecular Residual Disease and Risk Stratification for Children with Acute Myeloid Leukemia via Circulating Tumor DNA Open
Figure S4. The correlation of the VAFs in the patient-specific tumor mutation site detected in plasma ctDNA and matched MFC based MRD. Scatter plot of the 195 individual mutations detected by both methods (r=0.586, p<0.001).
View article: Data from Early Detection of Molecular Residual Disease and Risk Stratification for Children with Acute Myeloid Leukemia via Circulating Tumor DNA
Data from Early Detection of Molecular Residual Disease and Risk Stratification for Children with Acute Myeloid Leukemia via Circulating Tumor DNA Open
Purpose:Patient-tailored minimal residual disease (MRD) monitoring based on circulating tumor DNA (ctDNA) sequencing of leukemia-specific mutations enables early detection of relapse for pre-emptive treatment, but its utilization in pediat…
View article: Rational use of tigecycline and tigecycline blood concentration monitoring in patients with severe infection
Rational use of tigecycline and tigecycline blood concentration monitoring in patients with severe infection Open
Tigecycline, a tetracycline antibiotic, is widely used against antimicrobial resistance; therefore, medical staff should use tigecycline rationally to improve clinical efficacy and reduce resistance to this drug. The present study aimed to…
View article: [Clinical features and prognosis of juvenile myelomonocytic leukemia: an analysis of 63 cases].
[Clinical features and prognosis of juvenile myelomonocytic leukemia: an analysis of 63 cases]. Open
The PTPN11 gene was the most common mutant gene in JMML. Platelet count at diagnosis is associated with the prognosis in children with JMML. HSCT can improve the prognosis of children with JMML.
View article: A prospective multicenter study on varicella-zoster virus infection in children with acute lymphoblastic leukemia
A prospective multicenter study on varicella-zoster virus infection in children with acute lymphoblastic leukemia Open
Background and methods The study evaluated prognostic factors associated with varicella-zoster virus (VZV) infection and mortality in children with acute lymphoblastic leukemia (ALL) using data from the multicenter Chinese Children’s Cance…
View article: Connexin32 regulates expansion of liver cancer stem cells via the PI3K/Akt signaling pathway
Connexin32 regulates expansion of liver cancer stem cells via the PI3K/Akt signaling pathway Open
Liver cancer stem cells (LCSCs) are responsible for liver cancer recurrence, metastasis, and drug resistance. Previous studies by the authors demonstrated that upregulated expression of connexin 32 (Cx32) reversed doxorubicin resistance an…